By 
India is rapidly emerging as a global powerhouse in the bioeconomy, charting an impressive course towards a staggering $300 billion valuation by 2030. This ambitious target is underpinned by a vibrant ecosystem, evidenced by the soaring number of biotech startups now exceeding 11,800 across the nation.
The latest India Bioeconomy Report (IBER) 2026 paints a remarkably optimistic picture. In 2025, India’s bioeconomy surged to an impressive $195.3 billion, contributing approximately 4.8 percent to the national GDP. This isn’t just steady growth; it’s explosive. The sector witnessed a robust annual rise of 17–18 percent, ballooning from nearly $165 billion to $195 billion in just a single year.
This phenomenal expansion isn’t merely about numbers; it reflects a deep commitment to innovation, research, and entrepreneurial spirit within India. The proliferation of biotech startups, now numbering over 11,800, is a testament to the fertile ground for groundbreaking advancements in healthcare, agriculture, industrial biotechnology, and bio-energy. These companies are not only driving economic growth but also addressing critical global challenges through scientific ingenuity.
With such a dynamic trajectory and strong policy support, India is well-positioned to not only meet but potentially exceed its $300 billion bioeconomy goal, solidifying its role as a key player on the world’s biotechnology stage. The future looks incredibly bright for India’s bio-innovators!
Source: Original Article
Comments